Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-290 with Temozolomide in Recurrent IDH1/2-Mutant Gliomas
NCT03914742Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Feb 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pamiparib in glioma, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Feb 2020; status: completed.
02
Drugs
pamiparib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03914742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03914742.